38th Annual Meeting of the European Association for the Study of the Liver Istanbul

38th Annual Meeting of the European Association for the Study of the Liver

Istanbul, Turkey. March 28-April 1, 2003

Index

	Page One OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION (LDLT) : GRAFT SURVIVAL IS POOR ESPECIALLY IN HCV RECIPIENTS
	A RANDOMISED DOUBLE-BLIND PHASE II STUDY OF LAMIVUDINE (LAM) COMPARED TO LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL (ADV) FOR TREATMENT NAìVE PATIENTS WITH CHRONIC HEPATITIS B (CHB) : WEEK 52 ANALYSIS
	SIMVASTATIN AMMELIORATES THE INCREASED HEPATIC VASCULAR TONE IN PATIENTS WITH CIRRHOSIS
	Page two
	TENOFOVIR EFFECTIVELY INHIBITS VIRAL REPLICATION IN DIFFERENT PATIENT GROUPS WITH LAMIVUDINE RESISTANT HBV INFECTION
	LIVER FIBROSIS REGRESSES BETTER WITH PEGINTERFERON ALPHA AND URSODEOXYCHOLIC ACID TREATMENT THAN SPONTANEOUS RECOVERY
	EFFECT OF HBV AND HCV COINFECTION ON ANTI-VIRAL T CELL RESPONSES
	A RANDOMIZED CONTROLLED TRIAL OF PEGYLATED-INTERFERON ALPHA-2B + RIBAVIRIN VS INTERFERON ALPHA-2B + RIBAVIRIN IN HIV CO-INFECTED PATIENTS Page three COMBINATION OF PEGYLATED INTERFERON AND LAMIVUDINE IS SUPERIOR TO LAMIVUDINE MONOTHERAPY IN THE TREATMENT OF CHRONIC HEPATITIS B - A RANDOMIZED TRIAL
	PREDICTORS OF VIROLOGIC RESPONSE IN COMBINATION THERAPY WITH INTERFERON (IFN) ALFA 2B PLUS RIBAVIRIN OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION (LT)
	PREDCTIVE FACTORS OF HCC RECURRENCE AFTER LIVER TRANSPLANTATION (OLT) : AN INTERIM ANALYSIS
	Factors Associated With recurrence After Liver transplantation For Hepatocellular Carcinoma
	A STUDY OF THE PRESENCE OF HCV RNA IN SEMEN OF PATIENTS WITH CHRONIC HCV INFECTION Page Four
	EFFICACY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN FOR 24 WEEKS IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C FOLLOWED BY MONO OR COMBINATION THERAPY FOR 22 WEEKS: PRELIMINARY ANALYSIS OF AN OPEN, MULTICENTER, RANDOMIZED TRIAL
	Entecavir for HBV in Lamivudine Failures
	EFFICIENCY OF DNA VACCINE IN ASSOCIATION WITH LAMIVUDINE FOR CHRONIC HEPATITIS B THERAPY
	THE EFFECT OF PEGINTERFERON ALFA-2A (40 KD) ON LIVER HISTOLOGY IN CHRONIC HEPATITIS C: A META-ANALYSIS OF INDIVIDUAL PATIENTS DATA
	Clevudine, New Drug for HBV
	PHARMACOKINETICS OF PEGINTERFERON ALFA-2A (40KD, PEGASYS) COMPARED TO PEGINTERFERON ALFA-2B (12KD, PEGINTRON) IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C (CHC)
	Study Suggests More Than 48 Weeks Therapy for Patients with high baseline viral loads, HCV genotype 1, and cirrhosis may be necessary
	72 weeks HCV Therapy (PegIFN/RBV): is it effective?

HOME	Liver Cancer
FAQ Great Place To Start	Autoimmune Hepatitis
Have You Just Been Diagnosed ?	Other Medical Conditions & HCV
Glossary	HCV Worldwide News & Research
History Of HCV	HCV News Archives 2001-2002
Your Liver Functions	Internet Conference Reports on All New and Current HCV Therapies
Symptoms Of HCV	Nutrition & HCV
Transmission Of HCV	Interviews: Members & Professionals
Sex And HCV	HCV Support Groups Listed By State
Understanding Your Blood Tests Labs	Transplant Support Groups Listed By State
Monitoring Blood Work On Treatment	Insurance, Financial Aid & Free Meds
Liver Biopsy Understanding Your Results	How to Find a Doctor & What to Ask
Viral Loads	Members Share Their First Shot Experience
Genotypes	Shared Stories From Our Members
Infergen	Your Questions & HCV
Inhibitors & New Therapies	Chat Room & Message Boards
Peg Intron & Pegasys	Books On HCV
Help With Side Effects During Treatment	Food For The Soul Inspirational Stories
Drug Interactions & Treatment	Informative Links
Latest HCV Trials	Pictures Of Our Members
Liver Fibrosis	What's New at Janis and Friends
Cirrhosis	Sign Our Guestbook
Transplants	Contact Us mailto:JansDream@angelhaven.com
Current Transplant Research	In Memory Of Janis

Reviewed Feb 2004